These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31845839)

  • 1. Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and CommunicationR. Gulati, S. P. Psutka and R. Etzioni
    Shah N; Ioffe V
    J Urol; 2020 Apr; 203(4):841-842. PubMed ID: 31845839
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576-85.
    Montorsi F; Capitanio U; Rosiello G; Larcher A
    Eur Urol; 2022 Jun; 81(6):e149. PubMed ID: 35282969
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576-85.
    Wenzel M; Chun FK; Becker A
    Eur Urol; 2022 Nov; 82(5):e146-e147. PubMed ID: 35945085
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.
    Moul JW; Walsh PC; Rendell MS; Lynch HT; Leslie SW; Kosoko-Lasaki O; Fitzgibbons WP; Powell I; D'Amico AV; Catalona WJ
    J Urol; 2013 Sep; 190(3):1134-7. PubMed ID: 23871525
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies: R. Abouassaly, N. Tan, A. Moussa and J. S. Jones J Urol 2008; 180: 911-914.
    Feldstein MS; Hentz JG
    J Urol; 2009 Apr; 181(4):1960-1; author reply 1961. PubMed ID: 19251278
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W. Grundfest and L. S. Marks J Urol 2017;197:320-326.
    Yan W; Shang Z; Zhou Z
    J Urol; 2017 Sep; 198(3):708-709. PubMed ID: 28577379
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R. S. Lance, P. S. Nelson, I. M. Thompson, Jr., A. A. Wagner, J. T. Wei and D. W. Lin J Urol 2017;197:1026-1033.
    Denize J; Nouhaud FX; Cornu JN; Pfister C
    J Urol; 2017 Sep; 198(3):709-711. PubMed ID: 28579000
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W. Grundfest and L. S. Marks J Urol 2017;197:320-326.
    Orczyk C; Emberton M
    J Urol; 2017 Dec; 198(6):1436-1437. PubMed ID: 28888772
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: A multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641.
    Ayres BE; Bott SR; Barber NJ; Langley SE; Montgomery BS
    J Urol; 2010 Sep; 184(3):1223-4; author reply 1224. PubMed ID: 20655069
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110.
    Catalona WJ
    J Urol; 2011 Nov; 186(5):2131-2; author reply 2132. PubMed ID: 21945513
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Small prostate size and high grade disease--biology or artifact?: J. J. Liu, J. D. Brooks, M. Ferrari, R. Nolley and J. C. Presti, Jr. J Urol 2011; 185: 2108-2111.
    Calışkan S
    J Urol; 2011 Dec; 186(6):2504; author reply 2504-5. PubMed ID: 22019038
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    Patel N; Hu JC
    J Urol; 2018 Jun; 199(6):1633-1634. PubMed ID: 29555543
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
    Wang CS; Jhan JH; Li CC
    J Urol; 2019 Mar; 201(3):627-628. PubMed ID: 30759714
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
    Shah N; Ioffe V
    J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.